Working with patient organisations
At present the number of European patients able to access medicinal cannabis is estimated to be over 100,000* . However, as EU governments review and revise their guidelines, over 25 million patients may be able to access medicinal cannabis over the next 10 years in Europe**. This represents a massive unmet need for medicinal cannabis treatments, across a broad range of medical conditions, especially in the area of Pain Management.
*German Cannabis Report October 2018
**EU Cannabis Report January 2019
Key Priorities
Removing the regulatory and prescribing hurdles of pharmaceutical-grade medicinal cannabis in the EU and member states will enable innovative products to reach patients in a timely manner.
This requires co-operation and cross-working between the EUMCA and the wider industry stakeholders, including:
- Working with governments and healthcare professionals to assist and aid in their understanding of the benefits of cannabis for medicinal purposes
- Working with patient organisations to reduce inequalities for patients accessing medicinal cannabis-based medicines throughout the EU
- Working and collaborating with medical research charities and patient organisations to widen our scientific understanding on the benefits of medicinal cannabis and develop ethical, comprehensive educational materials which provide balanced, scientific information on its benefits
- Creating a transparent, credible and evidence-based knowledge exchange between medicinal cannabis stakeholders and patient organisations
- Ensuring that all key marketing communications are presented to patients in a standardised and ethical manner
Key Priorities
Removing the regulatory and prescribing hurdles of pharmaceutical-grade medicinal cannabis in the EU and member states will enable innovative products to reach patients in a timely manner.
This requires co-operation and cross-working between the EUMCA and the wider industry stakeholders, including:
- Working with governments and healthcare professionals to assist and aid in their understanding of the benefits of cannabis for medicinal purposes
- Working with patient organisations to reduce inequalities for patients accessing medicinal cannabis-based medicines throughout the EU
- Working and collaborating with medical research charities and patient organisations to widen our scientific understanding on the benefits of medicinal cannabis and develop ethical, comprehensive educational materials which provide balanced, scientific information on its benefits
- Creating a transparent, credible and evidence-based knowledge exchange between medicinal cannabis stakeholders and patient organisations
- Ensuring that all key marketing communications are presented to patients in a standardised and ethical manner
Our Vision
To advance patient access to medicinal cannabis treatments, and improve the health outcomes of patients across Europe
Our Mission
In order to improve the life and health outcomes of patients across Europe, the EUMCA facilitates the development of national government healthcare policies that advocates for the ethical prescription of pharmaceutical-grade medicinal cannabis, and advance patient access to treatments
If you are a Patient Association or Patient Advocacy Group interested in joining the EUMCA, please contact us on info@eumca.org or call +32 233 90 281
Our Vision
To advance patient access to medicinal cannabis treatments, and improve the health outcomes of patients across Europe
Our Mission
In order to improve the life and health outcomes of patients across Europe, the EUMCA facilitates the development of national government healthcare policies that advocate the ethical prescription of pharmaceutical-grade medicinal cannabis, and advance patient access to treatments
If you are a Patient Association or Patient Advocacy Group interested in joining the EUMCA, please contact us on info@eumca.org or call +32 233 90 281
Get in touch
Please submit your membership enquiry and our team will be in touch to discuss
Or call +32 233 90 281